These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 8380519

  • 21. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ.
    Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
    [No Abstract] [Full Text] [Related]

  • 22. Mechanisms of MPTP toxicity.
    Przedborski S, Jackson-Lewis V.
    Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
    [Abstract] [Full Text] [Related]

  • 23. Noradrenaline loss selectivity exacerbates nigrostriatal toxicity in different species of rodents.
    Fornai F, Bassi L, Bonaccorsi I, Giorgi F, Corsini GU.
    Funct Neurol; 1997; 12(3-4):193-8. PubMed ID: 9218976
    [No Abstract] [Full Text] [Related]

  • 24. Type B monoamine oxidase and neurotoxins.
    Naoi M, Maruyama W.
    Eur Neurol; 1993; 33 Suppl 1():31-7. PubMed ID: 8375430
    [Abstract] [Full Text] [Related]

  • 25. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI, Cavada C, de Sagarra MR, Cuadrado A.
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [Abstract] [Full Text] [Related]

  • 26. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia.
    Chiueh CC, Wu RM, Mohanakumar KP, Sternberger LM, Krishna G, Obata T, Murphy DL.
    Ann N Y Acad Sci; 1994 Nov 17; 738():25-36. PubMed ID: 7832434
    [Abstract] [Full Text] [Related]

  • 27. Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.
    Fujitake J, Kuno S, Mizuta E.
    Adv Neurol; 1990 Nov 17; 53():225-9. PubMed ID: 2239462
    [No Abstract] [Full Text] [Related]

  • 28. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
    Brücke T, Riederer P.
    Wien Med Wochenschr; 1986 Aug 31; 136(15-16):401-8. PubMed ID: 2878540
    [Abstract] [Full Text] [Related]

  • 29. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
    Sandler M, Glover V, Clow A, Jarman J.
    Adv Neurol; 1993 Aug 31; 60():238-41. PubMed ID: 8420141
    [No Abstract] [Full Text] [Related]

  • 30. In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP+, and MPP+.
    Obata T, Chiueh CC.
    J Neural Transm Gen Sect; 1992 Aug 31; 89(1-2):139-45. PubMed ID: 1329855
    [Abstract] [Full Text] [Related]

  • 31. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK, Choi BH, Huang X, Snyder BJ, Bukhari S, Kong TH, Park H, Park HC, Park SR, Ha Y.
    Eur J Neurosci; 2009 Mar 31; 29(5):891-900. PubMed ID: 19245369
    [Abstract] [Full Text] [Related]

  • 32. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
    Cohen G.
    Adv Neurol; 1987 Mar 31; 45():119-25. PubMed ID: 3030068
    [No Abstract] [Full Text] [Related]

  • 33. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct 31; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 34. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN, Thakar JH, Grimes JD.
    Adv Neurol; 1990 Oct 31; 53():219-23. PubMed ID: 2239461
    [No Abstract] [Full Text] [Related]

  • 35. Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism.
    Wesemann W, Solbach M, Nafe R, Grote C, Sontag KH, Riederer P, Jellinger K, Mennel HD, Clement HW.
    J Neural Transm Suppl; 1995 Oct 31; 46():175-82. PubMed ID: 8821053
    [Abstract] [Full Text] [Related]

  • 36. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
    Ungerstedt U, Ljungberg T, Steg G.
    Adv Neurol; 1974 Oct 31; 5():421-6. PubMed ID: 4531217
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease?
    Poirier J, Thiffault C.
    Eur Neurol; 1993 Oct 31; 33 Suppl 1():38-43. PubMed ID: 8375431
    [Abstract] [Full Text] [Related]

  • 40. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
    Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T.
    J Pharmacol Exp Ther; 2007 Jul 31; 322(1):274-81. PubMed ID: 17429058
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.